Compare Amgen, Inc. (AMGN) vs Cipher Mining Inc (CIFR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Cipher Mining Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Cipher Mining Inc trades at $21.88 (market cap $9.04B). The key difference: Amgen, Inc. is far larger — about 21.7× Cipher Mining Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Cipher Mining Inc pays none. Which is the better fit depends on your goals.
| AMGN | CIFR | |
|---|---|---|
Market Cap | $196.12B | $9.04B |
Sector | Health | Basic Materials |
52-Week High | $388.16 | $29.18 |
52-Week Low | $271.18 | $4.72 |
Enterprise Value | $241.41B | $13.07B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Cipher Digital (CIFR) trades at $22.11, down 4.94% today, amid a transition from Bitcoin mining to AI data center operations. The stock shows a bullish technical trend with strong analyst support (100% buy ratings) and a $32.81 consensus price target. However, fundamentals reveal deep losses with a -427.79% net income margin and negative cash flow from operations, offset by a promising $11.4B contracted revenue backlog from hyperscale leases.
The outlook hinges on successful execution of its AI infrastructure pivot, offering substantial upside if revenue ramps as planned by 2027. Key risks include persistent cash burn, high debt-to-asset ratio (64.51%), and reliance on future lease performance. Investors should weigh the growth potential against the company's current financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Cipher Mining Inc
Cipher Mining is an industrial-scale technology company focused on Bitcoin mining infrastructure. It develops and operates data centers in the US designed to strengthen the Bitcoin network and support decentralized finance.
Read more on CIFR →
